The agency is waiting on more data but said it “does not anticipate that Evusheld will neutralize XBB.1.5.” The FDA released a similar statement in October when subvariants BQ.1 and BQ.1.1 were dominant, but its emergency use authorization remained while other COVID-19 treatments, such as Eli Lilly’s bebtelovimab, were pulled.
AstraZeneca’s monoclonal is made up of two antibodies, and it is a preventive treatment administered every six months, according to the CDC.
Here is the reduction in susceptibility against some of the most dominant omicron subvariants, according to the FDA and CDC:
- BQ.1.1 (34.4 percent of cases) — not determined
- XBB (27.6 percent) — not determined
- BQ.1 (21.4 percent) — not determined
- BA.5 (3.7 percent) — 2.8- to 16-fold
- BN.1 (3 percent) — not determined
- BF.7 (2.2 percent) — not determined
- BA.2.75 (1.3 percent) — not determined
As the FDA awaits more information on Evusheld’s efficacy, it advised providers to “inform individuals of the increased risk, compared to other variants, for COVID-19 due to SARS-CoV-2 variants not neutralized by Evusheld.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.